Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy

被引：1
作者：
Wehbe, Eman [1 ,2 ]
Patanwala, Asad E. [1 ,3 ]
Lu, Christine Y. [1 ,4 ,5 ]
Kim, Hannah Yejin [1 ,2 ,6 ]
Stocker, Sophie L. [1 ,2 ,6 ,7 ]
Alffenaar, Jan-Willem C. [1 ,2 ,6 ]
机构：
[1] Univ Sydney, Fac Med & Hlth, Sch Pharm, Sydney, NSW 2006, Australia
[2] Westmead Hosp, Dept Pharm, Sydney, NSW 2145, Australia
[3] Royal Prince Alfred Hosp, Dept Pharm, Sydney, NSW 2050, Australia
[4] Royal North Shore Hosp, Dept Pharm, Sydney, NSW 2065, Australia
[5] Univ Sydney, Kolling Inst, Fac Med & Hlth, Northern Sydney Local Hlth Dist, Sydney, NSW 2065, Australia
[6] Univ Sydney, Sydney Inst Infect Dis, Sydney, NSW 2145, Australia
[7] St Vincents Hosp, Dept Clin Pharmacol & Toxicol, Sydney, NSW 2010, Australia
来源：
PHARMACEUTICS | 2024年 / 16卷 / 05期
关键词：
therapeutic drug monitoring; biomarkers; precision medicine; PK/PD; INVASIVE FUNGAL-INFECTIONS; CELL TRANSPLANT RECIPIENTS; CONSENSUS GUIDELINES; REAL-TIME; CYTOMEGALOVIRUS-INFECTION; PHARMACODYNAMICS; TUBERCULOSIS; DIAGNOSIS; IP-10; SERUM;
D O I：
10.3390/pharmaceutics16050677
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Due to variability in pharmacokinetics and pharmacodynamics, clinical outcomes of antimicrobial drug therapy vary between patients. As such, personalised medication management, considering both pharmacokinetics and pharmacodynamics, is a growing concept of interest in the field of infectious diseases. Therapeutic drug monitoring is used to adjust and individualise drug regimens until predefined pharmacokinetic exposure targets are achieved. Minimum inhibitory concentration (drug susceptibility) is the best available pharmacodynamic parameter but is associated with many limitations. Identification of other pharmacodynamic parameters is necessary. Repurposing diagnostic biomarkers as pharmacodynamic parameters to evaluate treatment response is attractive. When combined with therapeutic drug monitoring, it could facilitate making more informed dosing decisions. We believe the approach has potential and justifies further research.
引用
收藏
页数：13
相关论文
共 105 条
  • [1] Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases
    Ahmad, Anas
    Imran, Mohammad
    Ahsan, Haseeb
    [J]. PHARMACEUTICS, 2023, 15 (06)
  • [2] Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus
    Al-Nakeeb, Zaid
    Petraitis, Vidmantas
    Goodwin, Joanne
    Petraitiene, Ruta
    Walsh, Thomas J.
    Hope, William W.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (05) : 2735 - 2745
  • [3] Nano-biosensor based on the combined use of the dynamic and static light scattering for Aspergillus galactomannan analysis
    Alenichev, M. K.
    Levin, A. D.
    Yushina, A. A.
    Kostrikina, Eu S.
    Lebedin, Yu S.
    Andreeva, I. P.
    Grigorenko, V. G.
    Krylov, V. B.
    Nifantiev, N. E.
    [J]. SENSING AND BIO-SENSING RESEARCH, 2022, 35
  • [4] Clinical standards for the dosing and management of TB drugs
    Alffenaar, J. W. C.
    Stocker, S. L.
    Forsman, L. Davies
    Garcia-Prats, A.
    Heysell, S. K.
    Aarnoutse, R. E.
    Akkerman, O. W.
    Aleksa, A.
    van Altena, R.
    de Onata, W. Arrazola
    Bhavani, P. K.
    Van't Boveneind-Vrubleuskaya, N.
    Carvalho, A. C. C.
    Centis, R.
    Chakaya, J. M.
    Cirillo, D. M.
    Cho, J. G.
    Ambrosio, L. D.
    Dalcolmo, M. P.
    Denti, P.
    Dheda, K.
    Fox, G. J.
    Hesseling, A. C.
    Kim, H. Y.
    Koser, C. U.
    Marais, B. J.
    Margineanu, I
    Martson, A. G.
    Torrico, M. Munoz
    Nataprawira, H. M.
    Ong, C. W. M.
    Otto-Knapp, R.
    Peloquin, C. A.
    Silva, D. R.
    Ruslami, R.
    Santoso, P.
    Savic, R. M.
    Singla, R.
    Svensson, E. M.
    Skrahina, A.
    van Soolingen, D.
    Srivastava, S.
    Tadolini, M.
    Tiberi, S.
    Thomas, T. A.
    Udwadia, Z. F.
    Vu, D. H.
    Zhang, W.
    Mpagama, S. G.
    Schon, T.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2022, 26 (06) : 483 - +
  • [5] Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies
    Alffenaar, Jan-Willem C.
    de Steenwinkel, Jurriaan E. M.
    Diacon, Andreas H.
    Simonsson, Ulrika S. H.
    Srivastava, Shashikant
    Wicha, Sebastian G.
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [6] Microelectromechanical system-based biosensor for label-free detection of human cytomegalovirus
    Alzahrani, Khalid E.
    Assaifan, Abdulaziz K.
    Al-Gawati, Mahmoud
    Alswieleh, Abdullah M.
    Albrithen, Hamad
    Alodhayb, Abdullah
    [J]. IET NANOBIOTECHNOLOGY, 2023, 17 (01) : 32 - 39
  • [7] Host biomarkers for monitoring therapeutic response in extrapulmonary tuberculosis
    Ambreen, Atiqa
    Khaliq, Aasia
    Naqvi, Syed Zeeshan Haider
    Tahir, Amna
    Mustafa, Manal
    Chaudhary, Safee Ullah
    Mirza, Shaper
    Mustafa, Tehmina
    [J]. CYTOKINE, 2021, 142
  • [8] Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer
    Amin, Shahil
    Bathe, Oliver F.
    [J]. BMC CANCER, 2016, 16
  • [9] Bayot M. L., 2024, StatPearls
  • [10] (1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial
    Bloos, Frank
    Held, Juergen
    Kluge, Stefan
    Simon, Philipp
    Kogelmann, Klaus
    de Heer, Geraldine
    Kuhn, Sven-Olaf
    Jarczak, Dominik
    Motsch, Johann
    Hempel, Gunther
    Weiler, Norbert
    Weyland, Andreas
    Druener, Matthias
    Gruendling, Matthias
    Meybohm, Patrick
    Richter, Daniel
    Jaschinski, Ulrich
    Moerer, Onnen
    Guenther, Ulf
    Schaedler, Dirk
    Weiss, Raphael
    Putensen, Christian
    Castellanos, Ixchel
    Kurzai, Oliver
    Schlattmann, Peter
    Cornely, Oliver A.
    Bauer, Michael
    Thomas-Rueddel, Daniel
    [J]. INTENSIVE CARE MEDICINE, 2022, 48 (07) : 865 - 875
12345678910